Oncolytic Viruses plus Immune Checkpoint Inhibitors to Overcome Melanoma Drug Resistance

Rationale for combining oncolytic viruses and immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have transformed care for advanced melanoma, but clinical benefit is limited by resistance: nearly 50% of patients experience primary or acquired resistance and do not achieve meaningful responses. As ICIs are used earlier in disease courses, including adjuvant and neoadjuvant settings, the pool of patients with ICI‑resistant melanoma is growing. For those whose disease progresses after first‑line combined PD‑1 and CTLA‑4 blockade, effective salvage options are scarce.

Against this background, oncolytic viruses (OVs) are an attractive complementary strategy. OVs exert antitumor activity through two principal and complementary mechanisms: direct, selective tumor cell lysis and immunomodulatory remodeling of the tumor immune microenvironment. These properties provide a biologic rationale for combining OVs with ICIs to overcome immune resistance and re‑sensitize tumors to checkpoint blockade.

Clinical and preclinical evidence supporting OV–ICI synergy in melanoma

Recent preclinical and clinical work has advanced OV–ICI combinations from theoretical concepts to clinically evaluable regimens for refractory melanoma. Preclinical studies demonstrate that OVs can increase tumor immunogenicity, promote antigen presentation, and recruit effector immune cells into the tumor microenvironment, changes that can potentiate responses to ICIs. Clinical experience, evolving from early‑phase studies, supports the feasibility of co‑administration and provides preliminary evidence of synergistic antitumor activity in some patients with ICI‑resistant disease.

The review synthesizes this emerging body of evidence, highlighting that OV–ICI combinations are now a focus of translational and clinical investigation in melanoma. Specific trial outcomes, safety profiles, and agent‑level data were not detailed in the abstract; the article positions the combination approach as a promising but still investigational strategy.

Mechanisms of action: tumor cell lysis and remodeling of the tumor immune microenvironment

Oncolytic viruses act both as direct cytotoxic agents and as in situ immunotherapies. Tumor‑selective replication and lysis release tumor antigens and danger signals that can prime antitumor immunity. Concurrently, OVs can reshape the tumor immune microenvironment by increasing immune cell infiltration, enhancing antigen presentation, and altering cytokine milieus. These immune‑stimulatory effects may convert immunologically “cold” tumors into “hot” tumors that are more responsive to immune checkpoint inhibitors.

This dual mechanism underlies the rationale that OVs can overcome mechanisms of ICI resistance, including insufficient T‑cell infiltration, impaired antigen presentation, and suppressive microenvironmental factors. However, the review notes that mechanistic insights are still evolving and that interpatient heterogeneity influences the degree to which these mechanisms translate into clinical benefit.

Clinical challenges and translational barriers to OV–ICI combinations

Despite promise, several translational barriers limit broader implementation of OV–ICI regimens. These include:

• Interpatient heterogeneity in treatment response, driven by tumor‑intrinsic factors and microenvironmental differences.
• Uncertainty regarding optimal sequencing and dosing of the OV and ICI components — whether concurrent administration, priming with OV, or other temporal strategies yield superior outcomes has not been established in the available summary.
• Lack of validated predictive biomarkers to select patients most likely to benefit from combination therapy, complicating trial design and clinical decision making.

The review emphasizes that these challenges must be addressed to move OV–ICI combinations from experimental approaches to standard therapeutic options for patients with ICI‑resistant melanoma.

Implications for trial design, dosing, sequencing, and biomarker development

To accelerate clinical translation, the review calls for rationally designed trials informed by mechanistic biology. Key priorities include:

• Investigations that define optimal sequencing and dosing regimens for OV–ICI combinations, using translational endpoints to link schedule to immune modulation and clinical effect.
• Studies that account for interpatient heterogeneity, incorporating stratification or adaptive designs to identify subgroups with differential benefit.
• Integration of biomarker discovery and validation into clinical trials to establish predictive markers of response and resistance, which would enable precision immuno‑oncology approaches.

The authors argue that systematic synthesis of emerging clinical evidence and mechanistic insights can guide such trial design choices and refine combination strategies.

Conclusions and unmet needs in treating ICI‑resistant melanoma

Oncolytic viruses combined with immune checkpoint inhibitors represent a compelling approach to overcoming melanoma drug resistance by exploiting tumor cell lysis and immunomodulation of the tumor microenvironment. Clinical and preclinical advances have brought OV–ICI combinations into the realm of clinical evaluation for refractory melanoma. Nonetheless, significant translational gaps remain: heterogeneity in response, ambiguous optimal sequencing and dosing, and the current absence of validated predictive biomarkers. Addressing these unmet needs through focused translational research and thoughtfully designed clinical trials is necessary to expand effective salvage therapies for patients with ICI‑resistant melanoma.

Note: The abstract and PubMed entry summarize the review’s scope and conclusions; specific trial data, numerical outcomes, or detailed agent‑level results were not reported in the available abstract text.